Dr. Reddy’s began as an API manufacturer in 1984, producing high-quality APIs to first the Indian, and later, the international markets. In 1987, we started our formulations operations and, after becoming a force to reckon with in the Indian formulations market, went international in 1991.
Today, our value proposition to our customers derives from an optimal operating system in which operations, product development and marketing & sales are fully integrated. Operations and the supply chain are aligned to ensure high availability, pull based replenishment of products at the retail level and superior inventory turns to our customers. This advantage is combined with a highly effective prescription generation detailing effort.
A field force of over 2700 motivated and knowledgeable representatives supported by an integrated network of back-end services and armed with handheld devices for quick information access add value to every customer call and interaction.
Dr. Reddy’s - India today is more than a 200 million dollar venture with presence in almost all major therapeutic areas. Our finished dosage business in India started in 1986 with launch of Norilet (norfloxacin). Our market penetration through nearly 3000 sales force who connect to more than 3,00,000 doctors on a regular basis has yielded us reaching all corners of the country and providing affordable and innovative medicines in all major therapeutic areas like gastro-intestinal, oncology, pain management, cardiovascular, dermatology, diabetes, etc. Eight of our brands feature in the top-300 brands in India that include drugs like Stamlo, Reditux, Omez and Ketorol.
Alongside the presence of end-to-end pharmaceutical capabilities within the organization helps us cater customer and patient needs much more effectively. Medicines like for any other geography, we manufacture at our USFDA approved finished dosage facility with utmost importance on quality and efficacy of the drugs.
Recently we have deepened our focus into the rural markets in India to ensure the expansion of our reach. In this initiative we have collaborated with our CSR wing, Dr. Reddy’s Foundation to help us reach the millions who are still away from effective treatment and availability of the right medicines. Apart from manufacturing and distribution of medicines we also provide patient care through our various initiatives like Sparsh, Life at your Doorstep, etc. (where patients are given free treatment and medicines), and educate and create awareness among healthcare professionals through DRFHE to cater to the millions who are in need of proper treatment across the country.